Market news

FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

Lantheus Holdings (LNTH) said Monday that Curium resubmitted its pre-merger notification, beginning

Committed debt financing supporting the previously announced acquisition of Lantheus Holdings by Curium includes a senior secured multicurrency revolving credit facility and a $4.25 billion senior secured term loan B facility, according to a regulatory filing. In addition, Curium Midco entered into a separate commitment letter for a $1.125 billion PIK facility. The TLB and revolver will be incurred as additional facilities under Curium BidCo’s existing credit agreement, with JPMorgan as administ

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare equipment and supplies industry, including Lantheus (NASDAQ:LNTH) and its peers.

Lantheus Holdings (LNTH) wins FDA approval for Tauklarify, a radiodiagnostic agent designed to identify tau pathology in Alzheimer's through PET imaging. Read more here.

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

The companies anticipate closing the merger in H1 2027, pending regulatory clearances and approval from Lantheus’ shareholders.

Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal was unanimously approved by the Lantheus Board and is set to create a larger global player in diagnostic and therapeutic radiopharmaceuticals. The combined group is expected to integrate product portfolios and development pipelines across key imaging and oncology markets. Lantheus Holdings focuses on...

Lantheus (LNTH) has an average rating of overweight and mean price target of $113.36, according to a

CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.

Lantheus (LNTH) has agreed to be acquired and taken private by Curium in an up to $8 billion deal th

Curium has agreed to ⁠buy radiopharmaceutical company Lantheus Holdings in ​a deal worth ​up ​to $8 billion, the companies said on Monday.

Strategic transaction would bring Curium's theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business Total transaction consideration to Lantheus shareholders of up to $114.50 per share in cash for an aggregate transaction value of up to $8.0 billion – representing a premium of 38% to Lantheus’ unaffected 60-day volume-weighted average price and a premium of 29% to Lantheus’ unaffected 30-day volume-weighted average price Provide

Lantheus Holdings (LNTH) has an average rating of overweight and mean price target of $113.36, accor

Curium is in advanced talks to acquire Lantheus Holdings Inc (LNTH) in a deal valued at about $7 bil

Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights.

BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to re